Electrophysiological studies on the specificity of the cholecystokinin antagonist proglumide.
Recent evidence suggests that the glutaramic acid derivative proglumide (PROG) is a selective antagonist of cholecystokinin (CCK) in the rat CNS. The extent of this selectivity has now been characterized in more detail. Iontophoretic or intravenous (i.v.) administration of PROG was ineffective against the excitatory effect of iontophoretically applied neurotensin on midbrain dopamine (DA) cells, the excitatory effect of substance P and the inhibitory effect of Met-enkephalin on prefrontal cortical neurons, and the inhibitory effect of histamine on neurons of the sensorimotor cortex. In contrast, PROG blocked the excitatory effect of the C-terminal octapeptide of CCK in all 3 areas. Furthermore, iontophoretic PROG diminished, whereas CCK enhanced the inhibitory effect of similarly applied DA and GABA on DA cells. PROG pretreatment (1 mg/kg, i.v.) reduced the inhibitory potency and maximum effect of i.v. apomorphine (APO) on A9 DA neurons, while the inhibitory potency of APO was enhanced by i.v. CCK. Pretreatment with PROG plus CCK resulted in APO effects which were no different from those after PROG alone. Chronic treatment with PROG (1 mg/kg, p.o., 21 days) resulted in a return to normal of DA cell APO sensitivity. Combined, these findings suggest that PROG may be a relatively selective CCK antagonist, that the functional effect of dendritically released DA may be influenced by endogenously released CCK, and that tolerance may develop to the effects of chronic CCK receptor blockade.
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000502:physiology; D002540:Cerebral Cortex / Q000187:drug effects; D002766:Cholecystokinin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology; D004744:Enkephalin, Methionine / Q000494:pharmacology; D005973:Glutamine / Q000031:analogs & derivatives*; D008297:Male; D009496:Neurotensin / Q000494:pharmacology; D011377:Proglumide / Q000494:pharmacology*; D051381:Rats; D017981:Receptors, Neurotransmitter / Q000187:drug effects* / Q000502:physiology; D012970:Sodium Glutamate / Q000494:pharmacology; D013378:Substantia Nigra / Q000187:drug effects; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D017981:Receptors, Neurotransmitter; D005973:Glutamine; D009496:Neurotensin; D005680:gamma-Aminobutyric Acid; D004744:Enkephalin, Methionine; D002766:Cholecystokinin; D011377:Proglumide; D001058:Apomorphine; D004298:Dopamine; D012970:Sodium Glutamate